Shasqi
Biotechnology ResearchCalifornia, United States11-50 Employees
Shasqi is a San Francisco-based biotechnology company focused on oncology therapeutics. It uses click chemistry, a technology recognized with the 2022 Nobel Prize, to activate anticancer drugs specifically at the tumor site. The CAPAC platform separates the antibody-based targeting component from the drug payload and brings them back together through a click reaction at the tumor, enabling higher local drug doses while reducing exposure to healthy tissue. Its work involves building a diverse library of antibody-mediated tumor-targeting agents paired with various therapeutic payloads, designed to act only where the tumor is located. The approach seeks to improve the therapeutic index and lower systemic toxicity, aligning with goals in precision oncology. In 2023, Shasqi expanded its research collaboration with Johnson & Johnson Enterprise Innovation, indicating active collaboration with industry partners.
1-888-653-2347 
support@leadiq.com 
